SCHEMBL8228501

SCHEMBL8228501

C/C(=N\Nc1ccc(I)cc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 8/20 0.55
MEN1 O00255 8/20 0.55
KMT2A Q03164 8/20 0.55
RAB9A P51151 6/20 0.55
ALDH1A1 P00352 8/20 0.51
MAPT P10636 7/20 0.51
NPC1 O15118 6/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
HPGD P15428 1/20 0.51
KDM4E B2RXH2 4/20 0.49
POLB P06746 2/20 0.49
TDP1 Q9NUW8 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
CASP6 P55212 1/20 0.47
LMNA P02545 2/20 0.46
ATM Q13315 1/20 0.46
METTL3 Q86U44 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
GFER P55789 2/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1001084 1.00 GAA (0.55) GAAMEN1KMT2ARAB9AALDH1A1
SCHEMBL4413307 0.87 GAA (0.69) GAAMEN1KMT2ARAB9AALDH1A1
SCHEMBL3273659 0.87 GAA (0.69) GAAMEN1KMT2ARAB9AALDH1A1
SCHEMBL13345208 0.87 GAA (0.69) GAAMEN1KMT2ARAB9AALDH1A1
SCHEMBL11325414 0.84 MAPT (0.60) GAAMEN1KMT2ARAB9AALDH1A1
SCHEMBL11726036 0.84 MEN1 (0.57) GAAMEN1KMT2ARAB9AALDH1A1
SCHEMBL15187708 0.84 RAB9A (0.57) GAAMEN1KMT2ARAB9AALDH1A1
SCHEMBL8230499 0.83 ALDH1A1 (0.71) GAAMEN1KMT2ARAB9AALDH1A1
SCHEMBL22160190 0.82 ALDH1A1 (0.71) GAAMEN1KMT2ARAB9AALDH1A1
SCHEMBL11728616 0.82 GAA (0.55) GAAMEN1KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263624-B2 Aryl-substituted heterocycles, and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-09-11 US disclosed
US-8263624-B2 Aryl-substituted heterocycles, and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-09-11 US disclosed
US-20110015241-A1 SUBSTITUTED HETEROCYCLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-20 US disclosed
US-20110015241-A1 SUBSTITUTED HETEROCYCLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-20 US disclosed
EP-2029546-B1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER SCHERING PHARMA AG (DE) 2010-07-28 EP disclosed
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER HEALTHCARE AG 2010-02-04 US disclosed
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER HEALTHCARE AG 2010-02-04 US disclosed
WO-2007137791-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-12-06 WO disclosed
WO-2007137792-A1 SUBSTITUTED HETEROCYCLES AND USE THEREOF BAYER HEALTHCARE AG (DE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015241-A1 SUBSTITUTED HETEROCYCLES AND USE THEREOF F2, VKORC1, HMBS GAA 797/4885MEN1 366/4885KMT2A 2803/4885
US-20100029651-A1 ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF AHR, CYP2C19, PAH GAA 705/4885MEN1 620/4885KMT2A 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.